Targeting toll-like receptors in autoimmunity

Current Drug Targets

Volumn 10, Issue 11, 2009, Pages 1139-1155

  Midwood, K S ^a   Piccinini, A M ^a   Sacre, S ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Antagonist; Inflammatory bowel disease; Lupus; Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Therapies; Toll like receptors

Indexed keywords

AUTOANTIBODY; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CHAPERONIN; CHLOROQUINE; CPG OLIGODEOXYNUCLEOTIDE; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; DOUBLE STRANDED DNA ANTIBODY; GENE PRODUCT; GLATIRAMER; I KAPPA B KINASE BETA; IMIQUIMOD; IMMUNOMODULATING AGENT; METHOTREXATE; MIANSERIN; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MYELOID DIFFERENTIATION FACTOR 88; NEUTRALIZING ANTIBODY; OLIGODEOXYRIBONUCLEOTIDE; PAMAPIMOD; SM 360320; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 4 NEUTRALIZING ANTIBODY; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; Y CHROMOSOME LINKED AUTOIMMUNE ACCELERATOR;

ALLERGIC ENCEPHALOMYELITIS; ANTIBODY PRODUCTION; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CELL PROLIFERATION; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DEMYELINATION; DENDRITIC CELL; DRUG MECHANISM; DRUG MEGADOSE; ENTERITIS; EYE TOXICITY; GENE EXPRESSION; GENE LOCUS; GENETIC POLYMORPHISM; GRAFT REJECTION; HUMAN; INFLAMMATION; KERATINOCYTE; LOW DRUG DOSE; MULTIPLE SCLEROSIS; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; Y CHROMOSOME LINKAGE; DRUG EFFECTS; INNATE IMMUNITY; METABOLISM; PHYSIOLOGY;

AUTOIMMUNITY; HUMANS; IMMUNITY, INNATE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 70450199353     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009789735101     Document Type: Review

References (244)

1. Smolen JS, Maini RN. Interleukin-6: a new therapeutic target. Arthritis Res Ther 2006; 8(Suppl 2): S5.
2. Williams RO, Paleolog E, Feldmann M. Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases. Curr Opin Pharmacol 2007; 7(4): 412-417 (Pubitemid 47289266)
3. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009; 21(4): 317-337
4. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
5. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 1(2): 135-145
6. Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell 2002; 111(7): 927-930 (Pubitemid 36044685)
7. Jin MS, Lee JO. Structures of the toll-like receptor family and its ligand complexes. Immunity 2008; 29(2): 182-191
8. Akashi-Takamura S, Miyake K. TLR accessory molecules. Curr Opin Immunol 2008; 20(4): 420-425
9. Taylor KR, Yamasaki K, Radek KA, Di Nardo A, Goodarzi H, Golenbock D, et al. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem 2007; 282(25): 18265-18275
10. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009; 15(7): 774-780
11. Kenny EF, O'Neill LA. Signalling adaptors used by Toll-like receptors: an update. Cytokine 2008; 43(3): 342-349
12. Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon- beta. Nat Immunol 2008; 9(4): 361-368
13. Feldmann M, Maini RN. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008; 223: 7-19. (Pubitemid 351986171)
14. Sacre SM, Andreakos E, Kiriakidis S, Amjadi P, Lundberg A, Giddins G, et al. The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am J Pathol 2007; 170(2): 518-525 (Pubitemid 47339389)
15. Iwahashi M, Yamamura M, Aita T, Okamoto A, Ueno A, Ogawa N, et al. Expression of Toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 2004; 50(5): 1457-1467 (Pubitemid 38608067)
16. Seibl R, Birchler T, Loeliger S, Hossle JP, Gay RE, Saurenmann T, et al. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 2003; 162(4): 1221-1227 (Pubitemid 36350666)
17. Radstake TR, Roelofs MF, Jenniskens YM, Oppers-Walgreen B, van Riel PL, Barrera P, et al. Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis Rheum 2004; 50(12): 3856-3865 (Pubitemid 39643932)
18. Sacre SM, Drexler SK, Andreakos E, Feldmann M, Brennan FM, Foxwell BM. Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue. Ann Rheum Dis 2007; 66(Suppl 3): iii81-6.
19. Kilding R, Akil M, Till S, Amos R, Winfield J, Iles MM, et al. A biologically important single nucleotide polymorphism within the toll-like receptor-4 gene is not associated with rheumatoid arthritis. Clin Exp Rheumatol 2003; 21(3): 340-342 (Pubitemid 36747829)
20. Lamb R, Zeggini E, Thomson W, Donn R. Toll-like receptor 4 gene polymorphisms and susceptibility to juvenile idiopathic arthritis. Ann Rheum Dis 2005; 64(5): 767-769 (Pubitemid 40559307)
21. Radstake TR, Franke B, Hanssen S, Netea MG, Welsing P, Barrera P, et al. The Toll-like receptor 4 Asp299Gly functional variant is associated with decreased rheumatoid arthritis disease susceptibility but does not influence disease severity and/or outcome. Arthritis Rheum 2004; 50(3): 999-1001. (Pubitemid 38326201)
22. Kang ES, Lee J. Genotypic analysis of Asp299Gly and Thr399Ile polymorphism of Toll-like receptor 4 in systemic autoimmune diseases of Korean population. Rheumatol Int 2007; 27(9): 887-889 (Pubitemid 46906644)
23. Sanchez E, Orozco G, Lopez-Nevot MA, Jimenez-Alonso J, Martin J. Polymorphisms of toll-like receptor 2 and 4 genes in rheumatoid arthritis and systemic lupus erythematosus. Tissue Antigens 2004; 63(1): 54-57 (Pubitemid 38130443)
24. Sheedy FJ, Marinou I, O'Neill LA, Wilson AG. The Mal/TIRAP S180L and TLR4 G299D polymorphisms are not associated with susceptibility to, or severity of, rheumatoid arthritis. Ann Rheum Dis 2008; 67(9): 1328-1331
25. Kuuliala K, Orpana A, Leirisalo-Repo M, Kautiainen H, Hurme M, Hannonen P, et al. Polymorphism at position +896 of the toll-like receptor 4 gene interferes with rapid response to treatment in rheumatoid arthritis. Ann Rheum Dis 2006; 65(9): 1241-1243 (Pubitemid 44277406)
26. Sacre SM, Lo A, Gregory B, Simmonds RE, Williams L, Feldmann M, et al. Inhibitors of TLR8 reduce TNF production from human rheumatoid synovial membrane cultures. J Immunol 2008; 181(11): 8002-8009
27. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, van Lieshout AW, Sprong T, van den Hoogen FH, et al. The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum 2005; 52(8): 2313-2322
28. Ospelt C, Brentano F, Rengel Y, Stanczyk J, Kolling C, Tak PP, et al. Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum 2008; 58(12): 3684-3692
29. Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 2005; 52(9): 2656-2665 (Pubitemid 41369093)
30. Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci USA 2003; 100(11): 6646-6651
31. de Bouteiller O, Merck E, Hasan UA, Hubac S, Benguigui B, Trinchieri G, et al. Recognition of double-stranded RNA by human toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J Biol Chem 2005 ; 280(46): 38133-38145 (Pubitemid 43853708)
32. Gibbard RJ, Morley PJ, Gay NJ. Conserved features in the extracellular domain of human toll-like receptor 8 are essential for pHdependent signaling. J Biol Chem 2006; 281(37): 27503-27511
33. Rutz M, Metzger J, Gellert T, Luppa P, Lipford GB, Wagner H, et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol 2004; 34(9): 2541-2550 (Pubitemid 39302811)
34. Gerard HC, Wang Z, Wang GF, El-Gabalawy H, Goldbach-Mansky R, Li Y, et al. Chromosomal DNA from a variety of bacterial species is present in synovial tissue from patients with various forms of arthritis. Arthritis Rheum 2001; 44(7): 1689-1697 (Pubitemid 32642232)
35. Kempsell KE, Cox CJ, Hurle M, Wong A, Wilkie S, Zanders ED, et al. Reverse transcriptase-PCR analysis of bacterial rRNA for detection and characterization of bacterial species in arthritis synovial tissue. Infect Immun 2000; 68(10): 6012-6026 (Pubitemid 30739393)
36. van der Heijden IM, Wilbrink B, Tchetverikov I, Schrijver IA, Schouls LM, Hazenberg MP, et al. Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum 2000; 43(3): 593-598 (Pubitemid 30394951)
37. Chen T, Rimpilainen M, Luukkainen R, Mottonen T, Yli-Jama T, Jalava J, et al. Bacterial components in the synovial tissue of patients with advanced rheumatoid arthritis or osteoarthritis: analysis with gas chromatography-mass spectrometry and pan-bacterial polymerase chain reaction. Arthritis Rheum 2003; 49(3): 328-334 (Pubitemid 36682399)
38. Schumacher HR Jr, Arayssi T, Crane M, Lee J, Gerard H, Hudson AP, et al. Chlamydia trachomatis nucleic acids can be found in the synovium of some asymptomatic subjects. Arthritis Rheum 1999; 42(6): 1281-1284 (Pubitemid 29268967)
39. Dvorak HF, Senger DR, Dvorak AM, Harvey VS, McDonagh J. Regulation of extravascular coagulation by microvascular permeability. Science 1985; 227(4690): 1059-1061
40. McCachren SS, Lightner VA. Expression of human tenascin in synovitis and its regulation by interleukin-1. Arthritis Rheum 1992; 35(10): 1185-1196
41. Salter DM. Tenascin is increased in cartilage and synovium from arthritic knees. Br J Rheumatol 1993; 32(9): 780-786
42. Schett G, Redlich K, Xu Q, Bizan P, Groger M, Tohidast-Akrad M, et al. Enhanced expression of heat shock protein 70 (hsp70) and heat shock factor 1 (HSF1) activation in rheumatoid arthritis synovial tissue. Differential regulation of hsp70 expression and hsf1 activation in synovial fibroblasts by proinflammatory cytokines, shear stress, and antiinflammatory drugs. J Clin Invest 1998; 102(2): 302-311 (Pubitemid 28335189)
43. Scott DL, Delamere JP, Walton KW. The distribution of fibronectin in the pannus in rheumatoid arthritis. Br J Exp Pathol 1981; 62(4): 362-368 (Pubitemid 11000213)
44. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003; 48(4): 971-981 (Pubitemid 36418239)
45. Yu D, Rumore PM, Liu Q, Steinman CR. Soluble oligonucleosomal complexes in synovial fluid from inflamed joints. Arthritis Rheum 1997; 40(4): 648-654 (Pubitemid 27157569)
46. Deng GM, Nilsson IM, Verdrengh M, Collins LV, Tarkowski A. Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat Med 1999; 5(6): 702-705 (Pubitemid 29289436)
47. Cromartie WJ, Craddock JG, Schwab JH, Anderle SK, Yang CH. Arthritis in rats after systemic injection of streptococcal cells or cell walls. J Exp Med 1977; 146(6): 1585-1602
48. Williams RO. Models of rheumatoid arthritis. Ernst Schering Res Found Workshop 2005(50): 89-117.
49. Choe JY, Crain B, Wu SR, Corr M. Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling. J Exp Med 2003; 197(4): 537-542 (Pubitemid 36278608)
50. Abdollahi-Roodsaz S, Joosten LA, Koenders MI, Devesa I, Roelofs MF, Radstake TR, et al. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest 2008; 118(1): 205-216
51. Gondokaryono SP, Ushio H, Niyonsaba F, Hara M, Takenaka H, Jayawardana ST, et al. The extra domain A of fibronectin stimulates murine mast cells via toll-like receptor 4. J Leukoc Biol 2007; 82(3): 657-665
52. Pullerits R, Jonsson IM, Verdrengh M, Bokarewa M, Andersson U, Erlandsson-Harris H, et al. High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum 2003; 48(6): 1693-1700 (Pubitemid 36682378)
53. Holmoy T, Hestvik AL. Multiple sclerosis: immunopathogenesis and controversies in defining the cause. Curr Opin Infect Dis 2008; 21(3): 271-278 (Pubitemid 351634399)
54. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359(9313): 1221-1231
55. Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 1993; 6(4): 382-427. (Pubitemid 23306593)
56. Noseworthy JH. Progress in determining the causes and treatment of multiple sclerosis. Nature 1999; 399(6738 Suppl): A40-7.
57. Alvarez-Lafuente R, De las Heras V, Bartolome M, Picazo JJ, Arroyo R. Relapsing-remitting multiple sclerosis and human herpesvirus 6 active infection. Arch Neurol 2004; 61(10): 1523-1527
58. Rapp NS, Gilroy J, Lerner AM. Role of bacterial infection in exacerbation of multiple sclerosis. Am J Phys Med Rehabil 1995; 74(6): 415-418 (Pubitemid 26005308)
59. Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002; 125(Pt 5): 952-960 (Pubitemid 34464607)
60. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985; 1(8441): 1313-1315 (Pubitemid 15059152)
61. Schrijver IA, van Meurs M, Melief MJ, Wim Ang C, Buljevac D, Ravid R, et al. Bacterial peptidoglycan and immune reactivity in the central nervous system in multiple sclerosis. Brain 2001; 124(Pt 8): 1544-1554 (Pubitemid 32726768)
62. Andersson A, Covacu R, Sunnemark D, Danilov AI, Dal Bianco A, Khademi M, et al. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol 2008; 84(5): 1248-1255
63. Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002; 61(11): 1013-1021 (Pubitemid 35278723)
64. Billiau A, Matthys P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J Leukoc Biol 2001; 70(6): 849-860 (Pubitemid 33151123)
65. Heeger PS, Forsthuber T, Shive C, Biekert E, Genain C, Hofstetter HH, et al. Revisiting tolerance induced by autoantigen in incomplete Freund's adjuvant. J Immunol 2000; 164(11): 5771-5781 (Pubitemid 30389820)
66. Hamada T, Driscoll BF, Kies MW, Alvord EC Jr. LPS augments adoptive transfer of experimental allergic encephalomyelitis in the Lewis rat. Autoimmunity 1989; 2(4): 275-284 (Pubitemid 19101895)
67. Ichikawa HT, Williams LP, Segal BM. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J Immunol 2002; 169(5): 2781-2787
68. Segal BM, Chang JT, Shevach EM. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J Immunol 2000; 164(11): 5683-5688
69. Visser L, Jan de Heer H, Boven LA, van Riel D, van Meurs M, Melief MJ, et al. Proinflammatory bacterial peptidoglycan as a cofactor for the development of central nervous system autoimmune disease. J Immunol 2005; 174(2): 808-816 (Pubitemid 40094276)
70. Hansen BS, Hussain RZ, Lovett-Racke AE, Thomas JA, Racke MK. Multiple toll-like receptor agonists act as potent adjuvants in the induction of autoimmunity. J Neuroimmunol 2006; 172(1-2): 94-103.
71. Prinz M, Garbe F, Schmidt H, Mildner A, Gutcher I, Wolter K, et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest 2006; 116(2): 456-464 (Pubitemid 43228363)
72. Marta M, Andersson A, Isaksson M, Kampe O, Lobell A. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur J Immunol 2008; 38(2): 565-575
73. Zekki H, Feinstein DL, Rivest S. The clinical course of experimental autoimmune encephalomyelitis is associated with a profound and sustained transcriptional activation of the genes encoding tolllike receptor 2 and CD14 in the mouse CNS. Brain Pathol 2002; 12(3): 308-319 (Pubitemid 34743213)
74. Touil T, Fitzgerald D, Zhang GX, Rostami A, Gran B. Cutting Edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-beta. J Immunol 2006; 177(11): 7505-7509 (Pubitemid 44846263)
75. Burger D, Molnarfi N, Weber MS, Brandt KJ, Benkhoucha M, Gruaz L, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci USA 2009; 106(11): 4355-4359
76. Weber MS, Starck M, Wagenpfeil S, Meinl E, Hohlfeld R, Farina C. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 2004; 127(Pt 6): 1370-1378 (Pubitemid 38745515)
77. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369(9573): 1627-1640
78. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007; 117(3): 514-521 (Pubitemid 46348505)
79. Abreu MT, Fukata M, Arditi M. TLR signaling in the gut in health and disease. J Immunol 2005; 174(8): 4453-4460 (Pubitemid 40504521)
80. Gribar SC, Anand RJ, Sodhi CP, Hackam DJ. The role of epithelial Toll-like receptor signaling in the pathogenesis of intestinal inflammation. J Leukoc Biol 2008; 83(3): 493-498 (Pubitemid 351966856)
81. Melmed G, Thomas LS, Lee N, Tesfay SY, Lukasek K, Michelsen KS, et al. Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J Immunol 2003; 170(3): 1406-1415 (Pubitemid 36139508)
82. Otte JM, Cario E, Podolsky DK. Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology 2004; 126(4): 1054-1070 (Pubitemid 38451177)
83. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361(9356): 512-519
84. Hausmann M, Kiessling S, Mestermann S, Webb G, Spottl T, Andus T, et al. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 2002; 122(7): 1987-2000. (Pubitemid 34651441)
85. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000; 68(12): 7010-7017 (Pubitemid 32463415)
86. Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004; 113(9): 1296-1306 (Pubitemid 39069929)
87. Gardiner KR, Halliday MI, Barclay GR, Milne L, Brown D, Stephens S, et al. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 1995; 36(6): 897-901.
88. Pierik M, Joossens S, Van Steen K, Van Schuerbeek N, Vlietinck R, Rutgeerts P, et al. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis 2006; 2(1):1-8.
89. Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, Gustot T, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004; 53(7): 987-992 (Pubitemid 38824157)
90. Ouburg S, Mallant-Hent R, Crusius JB, van Bodegraven AA, Mulder CJ, Linskens R, et al. The toll-like receptor 4 (TLR4) Asp299Gly polymorphism is associated with colonic localisation of Crohn's disease without a major role for the Saccharomyces cerevisiae mannan-LBP-CD14-TLR4 pathway. Gut 2005; 54(3): 439-440 (Pubitemid 40299106)
91. Gazouli M, Mantzaris G, Kotsinas A, Zacharatos P, Papalambros E, Archimandritis A, et al. Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. World J Gastroenterol 2005; 11(5): 681-685 (Pubitemid 40220757)
92. De Jager PL, Franchimont D, Waliszewska A, Bitton A, Cohen A, Langelier D, et al. The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun 2007; 8(5): 387-397 (Pubitemid 47163102)
93. Rigoli L, Romano C, Caruso RA, Lo Presti MA, Di Bella C, Procopio V, et al. Clinical significance of NOD2/CARD15 and Toll-like receptor 4 gene single nucleotide polymorphisms in inflammatory bowel disease. World J Gastroenterol 2008; 14(28): 4454-4461
94. Torok HP, Glas J, Tonenchi L, Mussack T, Folwaczny C. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol 2004; 112(1): 85-91. (Pubitemid 38781061)
95. Baumgart DC, Buning C, Geerdts L, Schmidt HH, Genschel J, Fiedler T, et al. The c.1-260C>T promoter variant of CD14 but not the c.896A>G (p.D299G) variant of toll-like receptor 4 (TLR4) genes is associated with inflammatory bowel disease. Digestion 2007; 76(3-4): 196-202. (Pubitemid 351351673)
96. Lakatos PL, Lakatos L, Szalay F, Willheim-Polli C, Osterreicher C, Tulassay Z, et al. Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotypegenotype correlations. World J Gastroenterol 2005; 11(10): 1489-1495 (Pubitemid 40468084)
97. Brand S, Staudinger T, Schnitzler F, Pfennig S, Hofbauer K, Dambacher J, et al. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis 2005; 11(7): 645-652 (Pubitemid 40965520)
98. Gewirtz AT, Vijay-Kumar M, Brant SR, Duerr RH, Nicolae DL, Cho JH. Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2006; 290(6): G1157-63.
99. Saruta M, Targan SR, Mei L, Ippoliti AF, Taylor KD, Rotter JI. High-frequency haplotypes in the X chromosome locus TLR8 are associated with both CD and UC in females. Inflamm Bowel Dis 2009; 15(3): 321-327
100. Torok HP, Glas J, Tonenchi L, Bruennler G, Folwaczny M, Folwaczny C. Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology 2004; 127(1): 365-366 (Pubitemid 38962306)
101. Cario E. Therapeutic impact of toll-like receptors on inflammatory bowel diseases: a multiple-edged sword. Inflamm Bowel Dis 2008; 14(3): 411-421
102. Kitajima S, Takuma S, Morimoto M. Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp Anim 1999; 48(3): 137-143 (Pubitemid 129558679)
103. Araki A, Kanai T, Ishikura T, Makita S, Uraushihara K, Iiyama R, et al. MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. J Gastroenterol 2005; 40(1): 16-23. (Pubitemid 40796328)
104. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118(2): 229-241 (Pubitemid 38962578)
105. Fukata M, Michelsen KS, Eri R, Thomas LS, Hu B, Lukasek K, et al. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol 2005; 288(5): G1055-65.
106. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 2007; 132(4): 1359-1374 (Pubitemid 46627595)
107. Lee J, Mo JH, Katakura K, Alkalay I, Rucker AN, Liu YT, et al. Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol 2006; 8(12): 1327-1336 (Pubitemid 44835107)
108. Obermeier F, Dunger N, Strauch UG, Hofmann C, Bleich A, Grunwald N, et al. CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. Gastroenterology 2005; 129(3): 913-927 (Pubitemid 41242684)
109. Shi D, Das J, Das G. Inflammatory bowel disease requires the interplay between innate and adaptive immune signals. Cell Res 2006; 16(1): 70-74 (Pubitemid 43129310)
110. Vijay-Kumar M, Wu H, Aitken J, Kolachala VL, Neish AS, Sitaraman SV, et al. Activation of toll-like receptor 3 protects against DSS-induced acute colitis. Inflamm Bowel Dis 2007; 13(7): 856-864 (Pubitemid 47203863)
111. Rachmilewitz D, Karmeli F, Takabayashi K, Hayashi T, Leider- Trejo L, Lee J, et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 2002; 122(5): 1428-1441 (Pubitemid 34465184)
112. Obermeier F, Dunger N, Strauch UG, Grunwald N, Herfarth H, Scholmerich J, et al. Contrasting activity of cytosin-guanosin dinucleotide oligonucleotides in mice with experimental colitis. Clin Exp Immunol 2003; 134(2): 217-224 (Pubitemid 37372272)
113. Rhee SH, Im E, Riegler M, Kokkotou E, O'Brien M, Pothoulakis C. Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation. Proc Natl Acad Sci USA 2005; 102(38): 13610-13615 (Pubitemid 41420896)
114. Obermeier F, Dunger N, Deml L, Herfarth H, Scholmerich J, Falk W. CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice. Eur J Immunol 2002; 32(7): 2084-2092 (Pubitemid 34814566)
115. Criswell LA. The genetic contribution to systemic lupus erythematosus. Bull NYU Hosp Jt Dis 2008; 66(3): 176-183
116. Moser KL, Kelly JA, Lessard CJ, Harley JB. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009; 10(5): 373-379
117. Fessler BJ. Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis. Best Pract Res Clin Rheumatol 2002; 16(2): 281-291 (Pubitemid 36526644)
118. Caricchio R, McPhie L, Cohen PL. Ultraviolet B radiation-induced cell death: critical role of ultraviolet dose in inflammation and lupus autoantigen redistribution. J Immunol 2003; 171(11): 5778-5786 (Pubitemid 37467193)
119. Tan EM, Schur PH, Carr RI, Kunkel HG. Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest 1966; 45(11): 1732-1740
120. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301(1): 5-8. (Pubitemid 9226519)
121. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982; 25(4): 401-406
122. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000; 9(9): 664-671 (Pubitemid 32011791)
123. Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 1990; 33(11): 1665-1673
124. Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U, Neuhuber WL, et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002; 46(1): 191-201. (Pubitemid 34121664)
125. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41(7): 1241-1250 (Pubitemid 28313427)
126. Perl A, Gergely P Jr, Nagy G, Koncz A, Banki K. Mitochondrial hyperpolarization: a checkpoint of T-cell life, death and autoimmunity. Trends Immunol 2004; 25(7): 360-367 (Pubitemid 38780952)
127. Popovic K, Ek M, Espinosa A, Padyukov L, Harris HE, Wahren- Herlenius M, et al. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum 2005; 52(11): 3639-3645 (Pubitemid 41612235)
128. Urbonaviciute V, Furnrohr BG, Weber C, Haslbeck M, Wilhelm S, Herrmann M, et al. Factors masking HMGB1 in human serum and plasma. J Leukoc Biol 2007; 81(1): 67-74. (Pubitemid 46021254)
129. Urbonaviciute V, Furnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008; 205(13): 3007-3018
130. Papadimitraki ED, Choulaki C, Koutala E, Bertsias G, Tsatsanis C, Gergianaki I, et al. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006; 54(11): 3601-3611 (Pubitemid 44737172)
131. Komatsuda A, Wakui H, Iwamoto K, Ozawa M, Togashi M, Masai R, et al. Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 2008; 152(3): 482-487 (Pubitemid 351661498)
132. Ciferska H, Horak P, Konttinen YT, Krejci K, Tichy T, Hermanova Z, et al. Expression of nucleic acid binding Toll-like receptors in control, lupus and transplanted kidneys - a preliminary pilot study. Lupus 2008; 17(6): 580-585 (Pubitemid 351955435)
133. Migita K, Miyashita T, Maeda Y, Nakamura M, Yatsuhashi H, Kimura H, et al. Toll-like receptor expression in lupus peripheral blood mononuclear cells. J Rheumatol 2007; 34(3): 493-500. (Pubitemid 46364003)
134. Castiblanco J, Varela DC, Castano-Rodriguez N, Rojas-Villarraga A, Hincapie ME, Anaya JM. TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. Infect Genet Evol 2008; 8(5): 541-544
135. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, et al. The nature of the principal type 1 interferonproducing cells in human blood. Science 1999; 284(5421): 1835-1837 (Pubitemid 29275623)
136. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007; 13(5): 543-551 (Pubitemid 46828489)
137. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6(11): 823-835 (Pubitemid 44631651)
138. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005; 115(2): 407-417 (Pubitemid 40385482)
139. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416(6881): 603-607 (Pubitemid 34406754)
140. Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006; 203(3): 553-561
141. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005; 202(9): 1171-1177 (Pubitemid 41586947)
142. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005; 202(2): 321-331 (Pubitemid 41043827)
143. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006; 25(3): 417-428 (Pubitemid 44354217)
144. Berland R, Fernandez L, Kari E, Han JH, Lomakin I, Akira S, et al. Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity 2006; 25(3): 429-440 (Pubitemid 44376724)
145. Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S. Autoreactive B cell responses to RNArelated antigens due to TLR7 gene duplication. Science 2006; 312(5780): 1669-1672
146. Subramanian S, Tus K, Li QZ, Wang A, Tian XH, Zhou J, et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci USA 2006; 103(26): 9970-9975
147. Savarese E, Steinberg C, Pawar RD, Reindl W, Akira S, Anders HJ, et al. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum 2008; 58(4): 1107-1115 (Pubitemid 351564013)
148. Lee PY, Kumagai Y, Li Y, Takeuchi O, Yoshida H, Weinstein J, et al. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J Exp Med 2008; 205(13): 2995-3006.
149. Savarese E, Chae OW, Trowitzsch S, Weber G, Kastner B, Akira S, et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 2006; 107(8): 3229-3234
150. Tonel G, Conrad C. Interplay between keratinocytes and immune cells - recent insights into psoriasis pathogenesis. Int J Biochem Cell Biol 2009; 41(5): 963-968
151. Gladman DD. Psoriatic arthritis. Dermatol Ther 2009;22(1): 40-55.
152. Nograles KE, Brasington RD, Bowcock AM. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol 2009; 5(2): 83-91.
153. Hazard E, Cherry SB, Lalla D, Woolley JM, Wilfehrt H, Chiou CF. Clinical and economic burden of psoriasis. Manag Care Interface 2006; 19(4): 20-26
154. Miller LS. Toll-like receptors in skin. Adv Dermatol 2008; 24: 71-87.
155. Pivarcsi A, Bodai L, Rethi B, Kenderessy-Szabo A, Koreck A, Szell M, et al. Expression and function of Toll-like receptors 2 and 4 in human keratinocytes. Int Immunol 2003; 15(6): 721-730 (Pubitemid 36675803)
156. Song PI, Park YM, Abraham T, Harten B, Zivony A, Neparidze N, et al. Human keratinocytes express functional CD14 and toll-like receptor 4. J Invest Dermatol 2002; 119(2): 424-432 (Pubitemid 35001953)
157. Curry JL, Qin JZ, Bonish B, Carrick R, Bacon P, Panella J, et al. Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med 2003;127(2): 178-186 (Pubitemid 36231763)
158. Miller LS, Sorensen OE, Liu PT, Jalian HR, Eshtiaghpour D, Behmanesh BE, et al. TGF-alpha regulates TLR expression and function on epidermal keratinocytes. J Immunol 2005; 174(10): 6137-6143
159. Takeuchi J, Watari E, Shinya E, Norose Y, Matsumoto M, Seya T, et al. Down-regulation of Toll-like receptor expression in monocyte- derived Langerhans cell-like cells: implications of lowresponsiveness to bacterial components in the epidermal Langerhans cells. Biochem Biophys Res Commun 2003; 306(3): 674-679 (Pubitemid 37323815)
160. Candia L, Marquez J, Hernandez C, Zea AH, Espinoza LR. Tolllike receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity? J Rheumatol 2007; 34(2): 374-379
161. Rosenberg EW, Noah PW, Skinner RB Jr. Microorganisms and psoriasis. J Natl Med Assoc 1994; 86(4): 305-310
162. Kanda N, Tani K, Enomoto U, Nakai K, Watanabe S. The skin fungus-induced Th1- and Th2-related cytokine, chemokine and prostaglandin E2 production in peripheral blood mononuclear cells from patients with atopic dermatitis and psoriasis vulgaris. Clin Exp Allergy 2002; 32(8): 1243-1250 (Pubitemid 35007431)
163. Perez-Lorenzo R, Zambrano-Zaragoza JF, Moo-Castillo K, Luna- Vazquez DL, Ruiz-Guillermo L, Garcia-Latorre E. IgG class antibodies to heat shock-induced streptococcal antigens in psoriatic patients. Int J Dermatol 2003; 42(2): 110-115 (Pubitemid 41709839)
164. Gilliet M, Lande R. Antimicrobial peptides and self-DNA in autoimmune skin inflammation. Curr Opin Immunol 2008; 20(4): 401-407
165. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449(7162): 564-569 (Pubitemid 47525141)
166. Ting KM, Rothaupt D, McCormick TS, Hammerberg C, Chen G, Gilliam AC, et al. Overexpression of the oncofetal Fn variant containing the EDA splice-in segment in the dermal-epidermal junction of psoriatic uninvolved skin. J Invest Dermatol 2000; 114(4): 706-711 (Pubitemid 30227004)
167. Gilliet M, Conrad C, Geiges M, Cozzio A, Thurlimann W, Burg G, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004; 140(12): 1490-1495 (Pubitemid 39627441)
168. Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007; 20(4): 160-174 (Pubitemid 350029307)
169. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006; 54(3 Suppl 2): S67-80.
170. Schreiber S, Feagan B, D'Haens G, Colombel JF, Geboes K, Yurcov M, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, doubleblind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4(3): 325-334 (Pubitemid 43343889)
171. Nikas SN, Drosos AA. SCIO-469 Scios Inc. Curr Opin Investig Drugs 2004; 5(11): 1205-1212
172. Pettus LH, Wurz RP. Small molecule p38 MAP kinase inhibitors for the treatment of inflammatory diseases: novel structures and developments during 2006-2008. Curr top med chem 2008; 8(16): 1452-1467
173. Genovese MC. Inhibition of p38: has the fat lady sung? Arthritis Rheum 2009; 60(2): 317-320
174. Hill RJ, Dabbagh K, Phippard D, Li C, Suttmann RT, Welch M, et al. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. J Pharmacol Exp Ther 2008; 327(3): 610-619
175. Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexatecontrolled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009; 60(2): 335-344
176. Anderson DR, Meyers MJ, Vernier WF, Mahoney MW, Kurumbail RG, Caspers N, et al. Pyrrolopyridine inhibitors of mitogenactivated protein kinase-activated protein kinase 2 (MK-2). J Med Chem 2007; 50(11): 2647-2654 (Pubitemid 46896072)
177. Izmailova ES, Paz N, Alencar H, Chun M, Schopf L, Hepperle M, et al. Use of molecular imaging to quantify response to IKK-2 inhibitor treatment in murine arthritis. Arthritis Rheum 2007; 56(1): 117-128 (Pubitemid 46106184)
178. McIntyre KW, Shuster DJ, Gillooly KM, Dambach DM, Pattoli MA, Lu P, et al. A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum 2003; 48(9): 2652-2659 (Pubitemid 37129443)
179. MacMaster JF, Dambach DM, Lee DB, Berry KK, Qiu Y, Zusi FC, et al. An inhibitor of IkappaB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice. Inflamm Res 2003; 52(12): 508-511 (Pubitemid 38058225)
180. Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 1999; 284(5412): 321-325 (Pubitemid 129523450)
181. Loiarro M, Capolunghi F, Fanto N, Gallo G, Campo S, Arseni B, et al. Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol 2007; 82(4): 801-810 (Pubitemid 47511039)
182. Iyer S, Kontoyiannis D, Chevrier D, Woo J, Mori N, Cornejo M, et al. Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide. J Biol Chem 2000; 275(22): 17051-17057 (Pubitemid 30398947)
183. DeVry CG, Valdez M, Gao L, Wang J, Kotsch K, Volk HD, et al. RDP58, a novel immunomodulatory peptide, ameliorates clinical signs of disease in the Lewis rat model of acute experimental autoimmune encephalomyelitis. J Neuroimmunol 2004; 152(1-2): 33-43. (Pubitemid 38829700)
184. Murthy S, Flanigan A, Coppola D, Buelow R. RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis. Inflamm Res 2002; 51(11): 522-531 (Pubitemid 36009178)
185. Boismenu R, Chen Y, Chou K, El-Sheikh A, Buelow R. Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis. Ann Rheum Dis 2002; 61(Suppl 2): ii19-24.
186. Travis S, Yap LM, Hawkey C, Warren B, Lazarov M, Fong T, et al. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis 2005; 11(8): 713-719 (Pubitemid 41271174)
187. Mantovani A, Locati M, Vecchi A, Sozzani S, Allavena P. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol 2001; 22(6): 328-336 (Pubitemid 32675247)
188. Iwami KI, Matsuguchi T, Masuda A, Kikuchi T, Musikacharoen T, Yoshikai Y. Cutting edge: naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J Immunol 2000; 165(12): 6682-6686 (Pubitemid 32001129)
189. Brandl K, Gluck T, Hartmann P, Salzberger B, Falk W. A designed TLR4/MD-2 complex to capture LPS. J Endotoxin Res 2005; 11(4): 197-206. (Pubitemid 41358853)
190. Schnabl B, Brandl K, Fink M, Gross P, Taura K, Gabele E, et al. A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells. Biochem Biophys Res Commun 2008; 375(2): 210-214
191. Zunt SL, Burton LV, Goldblatt LI, Dobbins EE, Srinivasan M. Soluble forms of Toll-like receptor 4 are present in human saliva and modulate tumour necrosis factor-alpha secretion by macrophage- like cells. Clin Exp Immunol 2009; 156(2): 285-293
192. LeBouder E, Rey-Nores JE, Rushmere NK, Grigorov M, Lawn SD, Affolter M, et al. Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol 2003; 171(12): 6680-6689 (Pubitemid 37532100)
193. Tsujita T, Tsukada H, Nakao M, Oshiumi H, Matsumoto M, Seya T. Sensing bacterial flagellin by membrane and soluble orthologs of Toll-like receptor 5 in rainbow trout (Onchorhynchus mikiss). J Biol Chem 2004; 279(47): 48588-48597
194. Yilmaz A, Shen S, Adelson DL, Xavier S, Zhu JJ. Identification and sequence analysis of chicken Toll-like receptors. Immunogenetics 2005; 56(10): 743-753 (Pubitemid 40174969)
195. Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, Segal DM, et al. Structural basis of toll-like receptor 3 signaling with doublestranded RNA. Science 2008; 320(5874): 379-381 (Pubitemid 351555661)
196. Popa C, Abdollahi-Roodsaz S, Joosten LA, Takahashi N, Sprong T, Matera G, et al. Bartonella quintana lipopolysaccharide is a natural antagonist of Toll-like receptor 4. Infect Immun 2007; 75(10): 4831-4837
197. Abdollahi-Roodsaz S, Joosten LA, Roelofs MF, Radstake TR, Matera G, Popa C, et al. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum 2007; 56(9): 2957-2967 (Pubitemid 47502742)
198. Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 2004; 173(1): 145-150 (Pubitemid 38797335)
199. Johnson BJ, Le TT, Dobbin CA, Banovic T, Howard CB, Flores Fde M, et al. Heat shock protein 10 inhibits lipopolysaccharideinduced inflammatory mediator production. J Biol Chem 2005; 280(6): 4037-4047 (Pubitemid 40288567)
200. Athanasas-Platsis S, Corcoran CM, Kaye PL, Cavanagh AC, Morton H. Early pregnancy factor is required at two important stages of embryonic development in the mouse. Am J Reprod Immunol 2000; 43(4): 223-233 (Pubitemid 30229678)
201. Morton H, McKay DA, Murphy RM, Somodevilla-Torres MJ, Swanson CE, Cassady AI, et al. Production of a recombinant form of early pregnancy factor that can prolong allogeneic skin graft survival time in rats. Immunol Cell Biol 2000 ;78(6): 603-607
202. Zhang B, Walsh MD, Nguyen KB, Hillyard NC, Cavanagh AC, McCombe PA, et al. Early pregnancy factor treatment suppresses the inflammatory response and adhesion molecule expression in the spinal cord of SJL/J mice with experimental autoimmune encephalomyelitis and the delayed-type hypersensitivity reaction to trinitrochlorobenzene in normal BALB/c mice. J Neurol Sci 2003; 212 (1-2): 37-46. (Pubitemid 36693963)
203. Vanags D, Williams B, Johnson B, Hall S, Nash P, Taylor A, et al. Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. Lancet 2006; 368(9538): 855-863 (Pubitemid 44292809)
204. Broadley S, Vanags D, Williams B, Johnson B, Feeney D, Griffiths L, et al. Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis. Mult Scler 2009; 15(3): 329-336
205. Fort MM, Mozaffarian A, Stover AG, Correia Jda S, Johnson DA, Crane RT, et al. A synthetic TLR4 antagonist has antiinflammatory effects in two murine models of inflammatory bowel disease. J Immunol 2005; 174(10): 6416-6423 (Pubitemid 40663835)
206. Elass E, Aubry L, Masson M, Denys A, Guerardel Y, Maes E, et al. Mycobacterial lipomannan induces matrix metalloproteinase-9 expression in human macrophagic cells through a Toll-like receptor 1 (TLR1)/TLR2- and CD14-dependent mechanism. Infect Immun 2005; 73(10): 7064-7068 (Pubitemid 41368883)
207. Erridge C, Spickett CM, Webb DJ. Non-enterobacterial endotoxins stimulate human coronary artery but not venous endothelial cell activation via Toll-like receptor 2. Cardiovasc Res 2007; 73(1): 181-189 (Pubitemid 44937201)
208. Kumar MV, Nagineni CN, Chin MS, Hooks JJ, Detrick B. Innate immunity in the retina: Toll-like receptor (TLR) signaling in human retinal pigment epithelial cells. J Neuroimmunol 2004; 153(1-2): 7-15. (Pubitemid 38950922)
209. Andreakos E, Sacre SM, Smith C, Lundberg A, Kiriakidis S, Stonehouse T, et al. Distinct pathways of LPS-induced NF-kappa B activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP. Blood 2004; 103(6): 2229-2237 (Pubitemid 38326242)
210. Ungaro R, Fukata M, Hsu D, Hernandez Y, Breglio K, Chen A, et al. A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol 2009; 296(6): G1167-79.
211. Kokkola R, Li J, Sundberg E, Aveberger AC, Palmblad K, Yang H, et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 2003; 48(7): 2052-2058
212. Ranjith-Kumar CT, Duffy KE, Jordan JL, Eaton-Bassiri A, Vaughan R, Hoose SA, et al. Single-stranded oligonucleotides can inhibit cytokine production induced by human toll-like receptor 3. Mol Cell Biol 2008; 28(14): 4507-4519 (Pubitemid 351977750)
213. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005; 202(8): 1131-1139 (Pubitemid 41464506)
214. Ashman RF, Goeken JA, Drahos J, Lenert P. Sequence requirements for oligodeoxyribonucleotide inhibitory activity. Int Immunol 2005; 17(4): 411-420 (Pubitemid 40568116)
215. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007; 37(12): 3582-3586
216. Wang D, Bhagat L, Yu D, Zhu FG, Tang JX, Kandimalla ER, et al. Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9. J Med Chem 2009; 52(2): 551-558
217. Robbins M, Judge A, Liang L, McClintock K, Yaworski E, MacLachlan I. 2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther 2007; 15(9): 1663-1669 (Pubitemid 47289010)
218. Latz E, Verma A, Visintin A, Gong M, Sirois CM, Klein DC, et al. Ligand-induced conformational changes allosterically activate Tolllike receptor 9. Nat Immunol 2007; 8(7): 772-779 (Pubitemid 46965353)
219. Dong L, Ito S, Ishii KJ, Klinman DM. Suppressive oligonucleotides protect against collagen-induced arthritis in mice. Arthritis Rheum 2004; 50(5): 1686-1689 (Pubitemid 38608092)
220. Zeuner RA, Ishii KJ, Lizak MJ, Gursel I, Yamada H, Klinman DM, et al. Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides. Arthritis Rheum 2002; 46(8): 2219-2224 (Pubitemid 34894780)
221. Dong L, Ito S, Ishii KJ, Klinman DM. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. Arthritis Rheum 2005; 52(2): 651-658 (Pubitemid 40216332)
222. Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, et al. Inhibition of endotoxin response by e5564, a novel Tolllike receptor 4-directed endotoxin antagonist. J Pharmacol Exper ther 2003; 304(3): 1093-1102 (Pubitemid 36254422)
223. Nakamura M, Shimizu Y, Sato Y, Miyazaki Y, Satoh T, Mizuno M, et al. Toll-like receptor 4 signal transduction inhibitor, M62812, suppresses endothelial cell and leukocyte activation and prevents lethal septic shock in mice. Eur J Pharmacol 2007; 569(3): 237-243
224. Kyburz D, Brentano F, Gay S. Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol 2006; 2(9): 458-459 (Pubitemid 44340417)
225. Tehrani R, Ostrowski RA, Hariman R, Jay WM. Ocular toxicity of hydroxychloroquine. Semin Ophthalmol 2008; 23(3): 201-209
226. Hayashi T, Gray CS, Chan M, Tawatao RI, Ronacher L, McGargill MA, et al. Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7. Proc Natl Acad Sci USA 2009; 106(8): 2764-2769
227. Ziegler-Heitbrock HW. Molecular mechanism in tolerance to lipopolysaccharide. Inflammation 1995; 45(1): 13-26.
228. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50(5): 722-733 (Pubitemid 38580549)
229. Dummer R, Hauschild A, Becker JC, Grob JJ, Schadendorf D, Tebbs V, et al. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res 2008; 14(3): 856-864 (Pubitemid 351231170)
230. Horsmans Y, Berg T, Desager JP, Mueller T, Schott E, Fletcher SP, et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology (Baltimore, Md.) 2005; 42(3): 724-731 (Pubitemid 41233667)
231. Miller RL, Meng TC, Tomai MA. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect 2008; 21(2): 69-87.
232. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, et al. Immunotherapy with a ragweedtoll- like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355(14): 1445-1455 (Pubitemid 44511559)
233. Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, et al. Phase I trial of toll-like receptor 9 agonist PF- 3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res 2007; 13(20): 6168-6174 (Pubitemid 350075077)
234. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25(3): 283-291 (Pubitemid 26323465)
235. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alphainterferon therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115(3): 178-183
236. Lenert PS. Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res Ther 2006; 8(1): 203.
237. von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, Ku CL, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008; 321(5889): 691-696
238. Isnardi I, Ng YS, Srdanovic I, Motaghedi R, Rudchenko S, von Bernuth H, et al. IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 2008; 29(5): 746-757
239. Tabeta K, Hoebe K, Janssen EM, Du X, Georgel P, Crozat K, et al. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol 2006; 7(2): 156-164
240. Casrouge A, Zhang SY, Eidenschenk C, Jouanguy E, Puel A, Yang K, et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 2006; 314(5797): 308-312 (Pubitemid 44571977)
241. Sancho-Shimizu V, Zhang SY, Abel L, Tardieu M, Rozenberg F, Jouanguy E, et al. Genetic susceptibility to herpes simplex virus 1 encephalitis in mice and humans. Curr Opin Allergy Clin Immunol 2007; 7(6): 495-505. (Pubitemid 350076444)
242. Samuels J, Ng YS, Coupillaud C, Paget D, Meffre E. Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med 2005; 201(10): 1659-1667 (Pubitemid 40721009)
243. Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005; 201(5): 703-711 (Pubitemid 40395116)
244. Furst DE. The Risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2008 [Epub ahead of print].